1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Aripiprazole in the Treatment of Patients With Borderline Personality Disorder: A Double-Blind, Plac

Aripiprazole in the Treatment of Patients With Borderline Personality Disorder: A Double-Blind, Plac

  1. Calliope
    American Journal of Psychiatry 2006;163:833-838.

    Marius K. Nickel, M.D.; Moritz Muehlbacher, M.D.; Cerstin Nickel, M.D.; Christian Kettler, M.D.; Francisco Pedrosa Gil, M.D.; Egon Bachler, Ph.D.; Wiebke Buschmann, M.D.; Nadine Rother; Reinhold Fartacek, M.D.; Christoph Egger, M.D.; Javaid Anvar, M.D.; Wolfhardt K. Rother, M.D.; Thomas H. Loew, M.D.; Patrick Kaplan, M.D.

    Abstract
    Aripiprazole is a relatively new atypical antipsychotic agent that has been successfully employed in therapy for
    schizophrenia and schizoaffective disorders. A few neuroleptics have been used in therapy for patients with borderline personality disorder, which is associated with severe psychopathological symptoms. Aripiprazole, however, has not yet been tested for this disorder, and the goal of this study was to determine whether aripiprazole is effective in the treatment of several domains of symptoms of borderline personality disorder
    According to the intent-to-treat principle, significant changes in scores on most scales of the SCL-90-R, the HAM-D, the HAM-A, and all scales of the State-Trait Anger Expression Inventory were observed in the subjects treated with aripiprazole after 8 weeks. Self-injury occurred in the groups. The reported side effects were headache, insomnia, nausea, numbness, constipation, and anxiety.
    Conclusions: Aripiprazole appears to be a safe and effective agent in the treatment of patients with borderline personality disorder.